GLP-1 for Prediabetes

Prediabetes is a state of blood glucose above normal but below the diagnostic threshold for type 2 diabetes — defined as fasting glucose of 100-125 mg/dL or HbA1c of 5.7-6.4%. An estimated 98 million Americans have prediabetes, and without intervention roughly 15-30% will progress to type 2 diabetes within 5 years.

No GLP-1 receptor agonist is currently FDA-approved specifically for prediabetes. This is an off-label, prevention-focused application. The primary goal is not to treat an existing disease but to produce the sustained weight loss — typically 5-10%+ of body weight — that reliably reverses insulin resistance and can delay or prevent the onset of type 2 diabetes.

The evidence base for weight-loss-driven diabetes prevention is robust. GLP-1 drugs consistently produce larger weight reductions than lifestyle modification alone, and accumulating data from major obesity trials show high rates of prediabetes reversion to normoglycemia. The indication remains off-label, and prescribers typically document an obesity or weight-management basis for coverage purposes.

The Diabetes Prevention Program (DPP, Knowler 2002) established the benchmark: intensive lifestyle modification targeting 5-7% weight loss reduced type 2 diabetes incidence by 58% over approximately 3 years in adults with impaired glucose tolerance [1]. GLP-1 drugs consistently exceed this weight-loss target, making the prevention rationale compelling.

The 3-year SCALE Obesity and Prediabetes trial (le Roux 2017, Lancet) is the largest dedicated GLP-1 study in a prediabetes population. Liraglutide 3 mg versus placebo significantly reduced time to type 2 diabetes onset and produced a markedly higher rate of reversion from prediabetes to normoglycemia over 3 years of treatment [2].

STEP 1 (Wilding 2021) showed semaglutide 2.4 mg produced a mean 14.9% weight reduction in adults with overweight or obesity without T2D over 68 weeks — a population that included many participants with prediabetes at baseline [3]. Weight loss of this magnitude is consistently associated with prediabetes reversion in post-hoc analyses across the STEP program.

STEP 5 (Garvey 2022) demonstrated semaglutide 2.4 mg sustained 15.2% weight loss at 2 years versus 2.6% for placebo [4]. The durability is critical: short-term glucose improvements that rebound with weight regain carry limited long-term protective value, whereas sustained losses over years can produce durable normoglycemia.

SURMOUNT-1 (Jastreboff 2022), the pivotal tirzepatide obesity trial, included a substantial proportion of participants with prediabetes at baseline. Among those participants, a significantly higher proportion treated with tirzepatide reverted to normoglycemia by week 72 compared with placebo [6].

SELECT (Lincoff 2023) tested semaglutide 2.4 mg in adults with obesity and established cardiovascular disease but without diabetes. Semaglutide reduced 3-point MACE by 20% (HR 0.80, 95% CI 0.72-0.90) over ~3.3 years [5] — establishing that weight-loss-dose semaglutide has meaningful cardiovascular benefit even in the absence of diabetes, relevant to the many people with prediabetes who carry elevated CV risk.

A 2026 review synthesizing semaglutide and tirzepatide evidence in prediabetes concluded that both agents demonstrate clinically meaningful effects on glycemic reversion and cardiovascular risk reduction, supporting their off-label use as preventive pharmacotherapy in high-risk individuals, while noting that dedicated randomized trials with T2D prevention as the primary endpoint remain limited [7].

GLP-1 therapy for prediabetes is most appropriate as off-label prevention in people who have not achieved sufficient weight loss with lifestyle modification alone and who have additional risk factors: BMI above 30 kg/m², strong family history of T2D, metabolic syndrome, prior gestational diabetes, or A1c trending toward the upper prediabetes range (6.2-6.4%).

People with prediabetes who also have obesity (BMI ≥30, or ≥27 with a qualifying comorbidity) can be prescribed Wegovy (semaglutide 2.4 mg) or Zepbound (tirzepatide) under their FDA-approved obesity indication — an on-label approach that produces meaningful glycemic benefit as a secondary effect. The prescriber documents the obesity indication; the prediabetes improvement follows from weight loss.

Those with prediabetes alone, without obesity or other qualifying conditions, are less likely to have insurance coverage and must weigh out-of-pocket cost against benefit. Intensive lifestyle intervention (the Diabetes Prevention Program model) remains first-line and is highly effective — especially when structured programs are available.

The off-label status matters for reimbursement. Most insurers and Medicare do not cover GLP-1 medications specifically for prediabetes; coverage typically depends on meeting the obesity BMI threshold under the approved weight-management indication. Confirm coverage before prescribing.

Weight regain after stopping treatment is the primary limitation. STEP 1 withdrawal data showed that discontinuing semaglutide led to significant weight regain and blood sugar worsening within one year. Long-term, possibly indefinite use should be planned and discussed with the patient before initiation.

Lifestyle counseling — structured dietary changes and regular physical activity — should accompany any pharmacotherapy. The DPP demonstrated lifestyle alone is highly effective and more accessible; pharmacotherapy is best viewed as an adjunct or alternative when lifestyle targets cannot be sustained [1].

Prediabetes is asymptomatic and detected through routine labs. People on GLP-1 therapy for this indication should have A1c and fasting glucose monitored every 6-12 months to track whether normoglycemia is achieved and sustained, or whether progression is occurring despite treatment.

GI side effects (nausea, diarrhea, vomiting) are the primary tolerability concern, typically improving with slow dose titration over 16-20 weeks. These medications are contraindicated in personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2).